Market drivers behind the company’s strong performance, including a growing realisation among drug developers of the value of human challenge trials

Delivering the huge order backlog and growing the pipeline of potential new deals, and the coming launch of new challenge models

hVIVO’s unique model, and why as a world leader in human challenge trials it’s becoming a critical component of drug development

Discusses the recent Venn Life Sciences consultancy contract win

Using strengthening cash generation to start paying a dividend alongside continued investment in growth